Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful Postpartum CAR T-cell Salvage Therapy for Primary Mediastinal Large B-cell Lymphoma with Residual Disease after R-CHOP During Pregnancy.

Internal medicine (Tokyo, Japan)·2026
Same author

Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.

Blood advances·2026
Same author

Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.

British journal of haematology·2026
Same author

Disease status at CAR T-cell infusion in relapsed or refractory large B-cell lymphoma: prognostic significance for real-world outcomes, irrespective of bridging therapy.

Bone marrow transplantation·2026
Same author

Concurrent tumor lysis syndrome and 5-fluorouracil encephalopathy during the first cycle of zolbetuximab plus mFOLFOX6 for CLDN18.2-positive gastric cancer: a case report.

International cancer conference journal·2026
Same author

Single-cell transcriptomic profiling of platelet-adherent circulating tumor cells using a microcavity-gel manipulation platform.

Journal of bioscience and bioengineering·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 21, 2026

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
05:21

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay

Published on: September 13, 2024

[Cetuximab (Erbitux)].

Tatsu Shimoyama1

  • 1Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 22, 2009
PubMed
Summary
This summary is machine-generated.

Cetuximab, an EGFR-targeted therapy, shows clinical activity in metastatic colorectal cancer (CRC). Predictive markers like K-ras mutation status and skin rash help personalize treatment for better outcomes.

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Related Experiment Videos

Last Updated: Jun 21, 2026

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
05:21

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay

Published on: September 13, 2024

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Colorectal cancer (CRC) is a significant health concern, with the epidermal growth factor receptor (EGFR) pathway implicated in its development and progression.
  • Metastatic CRC necessitates targeted therapeutic strategies to improve patient outcomes.
  • Cetuximab, a monoclonal antibody targeting EGFR, is approved for metastatic CRC treatment in Japan.

Purpose:

  • To review recent clinical studies on cetuximab for metastatic CRC management.
  • To discuss predictive markers for cetuximab efficacy, aiding in treatment individualization.
  • To outline common toxicities associated with cetuximab therapy.

Summary:

  • Cetuximab demonstrates clinical activity and a distinct adverse event profile in metastatic CRC.
  • Predictive markers such as K-ras mutation status and skin rash are crucial for identifying patients likely to respond to anti-EGFR therapy.
  • Treatment individualization based on predictive markers and toxicity profiles is key for optimizing cetuximab use.

Impact:

  • Advances in understanding EGFR's role in CRC tumorigenesis and progression.
  • Provides a basis for personalized medicine approaches in metastatic CRC treatment.
  • Highlights the importance of predictive biomarkers in guiding therapeutic decisions for targeted cancer therapies.